NEPH Quote, Financials, Valuation and Earnings

Apyx Medical Corp. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -15.18%. Nephros, Inc.'s return on equity of 16.22% beat Apyx Medical Corp.'s return on equity of -146.08%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 62.5%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 56.25%. Given that Nephros, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Nephros, Inc. is more attractive than Apyx Medical Corp..

Nephros, Inc. has a beta of 1.397, which suggesting that the stock is 39.715% more volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.181%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Apyx Medical Corp. quarterly revenues of $12.9M. Nephros, Inc.'s net income of $337K is higher than Apyx Medical Corp.'s net income of -$2M. Notably, Nephros, Inc.'s price-to-earnings ratio is 28.96x while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.40x versus 3.22x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Accuray, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -13.47%. Nephros, Inc.'s return on equity of 16.22% beat Accuray, Inc.'s return on equity of -60.6%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 62.5%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 396.85%. Given that Accuray, Inc. has higher upside potential than Nephros, Inc., analysts believe Accuray, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.397, which suggesting that the stock is 39.715% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Nephros, Inc.'s net income of $337K is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Nephros, Inc.'s price-to-earnings ratio is 28.96x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.40x versus 0.13x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Owlet, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of 12.58%. Nephros, Inc.'s return on equity of 16.22% beat Owlet, Inc.'s return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 62.5%. On the other hand Owlet, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 57.85%. Given that Nephros, Inc. has higher upside potential than Owlet, Inc., analysts believe Nephros, Inc. is more attractive than Owlet, Inc..

Nephros, Inc. has a beta of 1.397, which suggesting that the stock is 39.715% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.713, suggesting its more volatile than the S&P 500 by 71.275%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Nephros, Inc.'s net income of $337K is lower than Owlet, Inc.'s net income of $4M. Notably, Nephros, Inc.'s price-to-earnings ratio is 28.96x while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.40x versus 1.80x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -316.61%. Nephros, Inc.'s return on equity of 16.22% beat Plus Therapeutics, Inc.'s return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 62.5%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1861.48%. Given that Plus Therapeutics, Inc. has higher upside potential than Nephros, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.397, which suggesting that the stock is 39.715% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Nephros, Inc.'s net income of $337K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Nephros, Inc.'s price-to-earnings ratio is 28.96x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.40x versus 4.49x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.